Impact of Anti–PD-1 and Anti–CTLA-4 on the Human Immunodeficiency Virus (HIV) Reservoir in People Living With HIV With Cancer on Antiretroviral Therapy: The AIDS Malignancy Consortium 095 Study | Zendy

Thomas A. Rasmussen | Zendy; Lakshmi Rajdev | Zendy; Ajantha Rhodes | Zendy; Ashanti Dantanarayana | Zendy; Surekha Tennakoon | Zendy; Socheata Chea | Zendy; Tim Spelman | Zendy; Shelly Lensing | Zendy; Rachel L. Rutishauser | Zendy; Sonia Bakkour | Zendy; Michael P. Busch | Zendy; Janet D. Siliciano | Zendy; Robert F. Siliciano | Zendy; Mark H. Einstein | Zendy; Dirk P. Dittmer | Zendy; Elizabeth Y. Chiao | Zendy; Steven G. Deeks | Zendy; Christine M. Durand | Zendy; Sharon R. Lewin | Zendy

Open Access

Impact of Anti–PD-1 and Anti–CTLA-4 on the Human Immunodeficiency Virus (HIV) Reservoir in People Living With HIV With Cancer on Antiretroviral Therapy: The AIDS Malignancy Consortium 095 Study

Author(s) -

Thomas A. Rasmussen,

Lakshmi Rajdev,

Ajantha Rhodes,

Ashanti Dantanarayana,

Surekha Tennakoon,

Socheata Chea,

Tim Spelman,

Shelly Lensing,

Rachel L. Rutishauser,

Sonia Bakkour,

Michael P. Busch,

Janet D. Siliciano,

Robert F. Siliciano,

Mark H. Einstein,

Dirk P. Dittmer,

Elizabeth Y. Chiao,

Steven G. Deeks,

Christine M. Durand,

Sharon R. Lewin

Publication year - 2021

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciaa1530

Subject(s) - medicine , nivolumab , ipilimumab , immunology , oncology , viral load , cancer , immune checkpoint , virology , immunotherapy , virus

Antibodies to programmed cell death 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) may perturb human immunodeficiency virus (HIV) persistence during antiretroviral therapy (ART) by reversing HIV latency and/or boosting HIV-specific immunity, leading to clearance of infected cells. We tested this hypothesis in a clinical trial of anti-PD-1 alone or in combination with anti-CTLA-4 in people living with HIV (PLWH) and cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research